ASO GROUP Ltd Makes New Investment in DaVita Inc. $DVA

ASO GROUP Ltd purchased a new position in shares of DaVita Inc. (NYSE:DVA) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,291 shares of the company’s stock, valued at approximately $488,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DVA. Elevation Wealth Partners LLC grew its stake in shares of DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after buying an additional 165 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of DaVita in the second quarter valued at about $43,000. iSAM Funds UK Ltd acquired a new stake in shares of DaVita in the third quarter valued at about $46,000. Stance Capital LLC acquired a new stake in shares of DaVita in the third quarter valued at about $47,000. Finally, Fideuram Asset Management Ireland dac acquired a new stake in shares of DaVita in the fourth quarter valued at about $49,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on DVA. Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a research note on Monday. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. UBS Group increased their target price on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, Barclays increased their target price on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $199.17.

Insider Buying and Selling

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This trade represents a 27.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.50% of the stock is currently owned by corporate insiders.

DaVita Stock Up 2.6%

Shares of NYSE DVA opened at $203.72 on Friday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $205.42. The business has a 50 day moving average price of $174.98 and a two-hundred day moving average price of $145.65. The firm has a market cap of $13.08 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 0.65 and a beta of 0.91.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the firm earned $2.00 EPS. DaVita’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts anticipate that DaVita Inc. will post 15.07 earnings per share for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.